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Introduction: In spite of improving results, the treatment of in-stent restenosis (ISR) of bare-metal stents 
(BMS), and particularly drug-eluting stents (DES), is a challenging clinical problem. There are promising but 
limited follow-up data concerning drug-eluting balloons in the treatment of BMS and DES restenosis. The 
goal of this real-world registry was to assess the long-term safety and efficacy of drug-eluting balloons in 
the treatment of BMS and DES restenosis.
Methods: In this prospective registry, 82 patients with BMS or DES restenosis treated with paclitaxel-eluting 
balloons were enrolled. The primary endpoint was ischemia-driven target lesion revascularization (TLR); a 
secondary endpoint was the rate of major adverse cardiac events (MACE) at 28 months.
Results: Thirty-five patients (42.7%) had DES ISR and 16 patients (19.5%) presented with an acute coronary 
syndrome. The success rate of drug-eluting balloon inflation was 97.6%. The median (interquartile range) 
duration of follow up was 28.0 (25.0-30.3) months. The rate of TLR was 24.5%, and was not significantly 
higher in the DES-ISR group than in the BMS-ISR group: 29.0% vs. 21.1%, respectively (p=0.687). There 
were two cases of definite stent thrombosis in the BMS-ISR group and one probable subacute stent throm-
bosis in the DES-ISR group. The overall MACE rate was 37.0% and did not differ between the DES-ISR and 
BMS-ISR group (40.8% vs. 34.7%, respectively; p=0.994).
Conclusions: This real-world registry provided less favorable long-term results for drug-eluting balloons in 
the treatment of BMS restenosis and in DES restenosis, compared to the promising mid-term results of pre-
vious studies. The TLR rate was slightly but not significantly higher after DES restenosis compared to BMS 
restenosis treatment.
C ompared to the bare-metal stent (BMS) era, the rate of in-stent re-stenosis (ISR) has been reduced 
by the introduction of drug-eluting stents 
(DES); however, it remains a challenge 
for interventional cardiology after coro-
nary stent implantation.1-5 We know from 
clinical observations that a significant per-
centage of ISR cases present as acute cor-
onary syndrome;6,7 thus, the first-line chal-
lenge is to reduce the frequency of ISR 
by using modern drug-eluting stents with 
a proper implantation technique. In cas-
es where ISR develops, more therapeutic 
options are available. There are reports 
of high pressure balloon angioplasty, ad-
ditional stent (commonly DES) implan-
tation,8-11 and some more sophisticated 
methods, such as intravascular brachy-
therapy and laser-based therapy, but their 
long-term angiographic and hemodynam-
ic results proved to be less promising.12-14 
However, it is well known that re-reste-
nosis in a previously restenotic stent, even 
treated by balloon angioplasty or stenting, 
usually represents a more complex clinical 
and angiographic situation with a poorer 
outcome.15
The concept of stentless drug deliv-
ery to the coronary wall combines the ad-
370 • HJC (Hellenic Journal of Cardiology)
B. Berta et al
vantages of a well-controlled local drug action with-
out acute and chronic inflammation triggered by the 
stent components. In the recent past, there have been 
several reports of drug-eluting balloons showing a 
potential beneficial effect in ISR treatment.16-23 Al-
though the first target of this kind of invasive treat-
ment was the ISR, recent studies confirmed the ef-
ficacy of drug-eluting balloon treatment in de novo 
lesions,24 as well as in small vessels25 and in bifurca-
tion coronary stenosis.26 There is one trial, neverthe-
less, that failed to confirm the superiority of drug-
eluting balloons in thrombotic coronary lesions fol-
lowed by BMS implantation, compared to BMS only, 
in patients with ST-elevation myocardial infarction.27 
These results, generally supported by small cohorts of 
patients, make the need for real-life experience more 
pronounced.
The aim of our prospective registry was to eval-
uate the efficacy and safety of drug-eluting balloon 
treatment in BMS and DES restenosis.
Methods
Study population
The clinical and angiographic data of 82 consecutive 
patients treated by drug-eluting balloon for coronary 
ISR between May 2009 and March 2011 were evalu-
ated in a prospective registry at the high-volume cath-
eter laboratory (>1500 interventions/year) of Sem-
melweis University Heart Center. All patients en-
tered in our registry underwent coronary dilatation 
with a drug-eluting balloon for hemodynamically sig-
nificant ISR presenting as acute coronary syndrome 
or stable angina. There were no exclusion criteria. 
The enrolled patients were informed about the data-
base and the processing of their relevant clinical base-
line and follow-up data before they gave written con-
sent. The local Ethics Committee provided ethical ap-
proval for this study, which satisfied the principles of 
the Declaration of Helsinki.
Coronary angiography
The coronary angiography was performed accord-
ing to international recommendations, using the ra-
dial approach by preference. Every stenosis localized 
within the edges of a stent was measured from at least 
two views, without shortening of the current segment, 
by two skilled independent interventional cardiolo-
gists. Significant stenosis was considered to be pres-
ent if the diameter stenosis was >50% in at least one 
of the views of the observed coronary segment. A 
conventional balloon was used for predilation of the 
target lesion. The recommended balloon-to-artery 
ratio was 1:1 and the balloon used was 5 mm short-
er than the drug-eluting study balloon. During the 
procedures, three different types of paclitaxel-elut-
ing balloons were used: SeQuent Please (B. Braun 
Melsungen AG, Berlin, Germany), Dior (Eurocor 
GmbH, Bonn, Germany), and Pantera Lux (Biotron-
ik, Berlin, Germany). The choice among these bal-
loon types was left to the discretion of the operators. 
The recommended inflation time of the drug-eluting 
balloon was 45 seconds for the Pantera Lux balloon, 
and 60 seconds for both the Dior and the SeQuent 
Please balloon. The procedure was evaluated as suc-
cessful if the residual stenosis was <30% and no cor-
onary dissection or occlusion was visible. In the case 
of dissection an additional stent was implanted.
Study definitions
The primary endpoint was clinically driven target le-
sion revascularization (TLR). Patients who under-
went repeat percutaneous coronary intervention or 
bypass surgery for myocardial ischemia caused by 
≥50% diameter stenosis within or 5 mm proximal or 
distal to the drug-eluting balloon treated stent were 
deemed to have TLR. The grade of in-stent reste-
nosis was estimated visually. The secondary end-
point was major adverse cardiac events (MACE): 
the composite endpoint of all-cause death, definite 
and probable stent thrombosis, myocardial infarc-
tion and TLR. Stent thrombosis was defined ac-
cording to the Academic Research Consortium cri-
teria.28 Stent thrombosis included both definite and 
probable categories. Stent thrombosis was defined 
as acute if it occurred during the first 24 hours, sub-
acute in the first 30 days, late after one month, and 
very late if it occurred more than one year after the 
percutaneous coronary intervention. Periprocedural 
myocardial infarction (during the first 48 hours) was 
defined as a creatine-kinase-MB isoenzyme eleva-
tion to more than 3 times the upper range limit. Af-
ter the periprocedural period, any elevation of tro-
ponin T above the upper range limit was considered 
as myocardial infarction. An independent panel of 
physicians, blinded to the procedural information, 
verified the clinical events using the source docu-
mentation.
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Antithrombotic regimen
All patients received a loading dose of 300 mg of as-
pirin and 600 mg of clopidogrel before or at the time 
of the procedure, if they were not already on mainte-
nance therapy. During the procedure, unfractionated 
heparin (100 U/kg body weight) was administered to 
every patient. Glycoprotein IIb/IIIa antagonists were 
used at the operators’ discretion. Clopidogrel 75 mg 
daily was recommended for at least 6 months and as-
pirin 100 mg daily was continued indefinitely.
Follow up
Clinical follow up was performed 2 months after the 
index procedure, then once every 5 months in the 
outpatient clinic or by telephone contact. If a patient 
was lost to follow up, the National Insurance Fund 
was contacted. No routine angiographic check was 
performed.
Statistics
Categorical variables are expressed as absolute num-
bers and percentages, while continuous variables are 
given as mean ± standard deviation or median (inter-
quartile range) as appropriate. Categorical variables 
were compared using the chi-square test or Fisher’s 
exact test, as appropriate. Continuous variables were 
compared using the parametric Student t-test. Sur-
vival curves were constructed by the Kaplan–Meier 
method and a log-rank test was performed to com-
pare them. A multivariable Cox proportional-hazards 
model was used to identify independent predictors of 
TLR and MACE in patients with DES or BMS ISR. 
A stepwise multivariate analysis was performed us-
ing the variables presented in Table 1 and the type of 
drug-eluting balloon, type of arterial approach, an-
giographic pattern of the ISR (focal or diffuse/occlu-
sive), and the type of stent (BMS or DES) in which 
the ISR developed. A p-value <0.05 was considered 
statistically significant. PASW 18.0 (IBM Corpora-
tion New York, USA) statistical software was used 
for all statistical calculations.
Results
Baseline demographic data
The enrolled patient population contained 82 sub-
jects; 48.7% were male and the mean age was 63.4 ± 
10.3 years. The typical study individual was affected 
by several cardiovascular risk factors and extensive 
coronary artery disease. The frequency of diabetes 
mellitus was 36.6%, 70.7% had a previous myocardial 
infarction, and 19.5% of the patients presented with 
an acute coronary syndrome, defined as unstable an-
gina, non ST-elevation myocardial infarction or ST-
elevation myocardial infarction. Although some of 
the patients with acute coronary syndrome suffered 
from low cardiac function, no intra-aortic balloon 
pump insertion was needed. The detailed baseline 
conditions are shown in Table 1.
All drug-eluting balloon dilatations were per-
formed inside an in-stent restenosis; 42.7% of the cas-
es were DES restenosis and 57.3% were BMS reste-
nosis. Sixteen of the 35 DES restenosis patients had 
restenosis in first generation DES (Cypher or Tax-
us) and the other 19 in second generation DES (En-
deavor, Promus, Xience). The type of anti-restenotic 
Table 1. Baseline demographic data.
 Entire registry BMS-ISR (n=47) DES-ISR (n=35) p
Age (years) 63.4 ± 10.3 63.6 ± 10.2 62.7 ± 10.9 0.569
Men, n (%) 40 (48.7) 24 (51.1) 16 (45.7) 0.632
Diabetes mellitus, n (%) 30 (36.6) 18 (38.3) 12 (34.3) 0.709
Arterial hypertension, n (%) 81 (98.8) 46 (97.9) 35 (100.0) 0.385
Dyslipidemia, n (%) 74 (90.2) 41 (87.2) 33 (94.3) 0.287
Current smoker, n (%) 19 (23.2) 11 (23.4) 8 (22.9) 0.954
Peripheral arterial diseases, n (%) 16 (19.5) 7 (14.9) 9 (25.7) 0.221
Renal failure, n (%) 7 (8.5) 4 (8.5) 3 (8.6) 0.992
Previous myocardial infarction, n (%) 58 (70.7) 36 (76.6) 22 (62.9) 0.176
Previous CABG, n (%) 12 (14.6) 3 (6.4) 9 (25.7) 0.014
Family history of CAD, n (%) 9 (11.0) 5 (10.6) 4 (11.4) 0.910
Acute coronary syndrome, n (%) 16 (19.5) 11 (25.6) 5 (14.3) 0.306
CABG – coronary artery bypass surgery; CAD – coronary artery disease.
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drug eluted by the stent was sirolimus in 8 patients, 
paclitaxel in 8 patients, zotarolimus in 4 patients, and 
everolimus 15 patients.
Finally, in 82 patients, 82 equal ISR lesions were 
treated with inflation of 82 drug-eluting balloons. The 
most common ISR pattern29 was the diffuse intra-
stent pattern (35.4%), while the total rate of diffuse 
intra-stent, diffuse-proliferative and total occlusion 
ISR pattern was 46.4%. ISR in the right coronary ar-
tery (n=34) or left anterior descending coronary artery 
(n=28) was the most frequent target of the interven-
tion; however, some cases presented with lesions in the 
left main stem (n=4), left circumflex coronary artery 
(n=16), or ramus intermedius (n=1). In 3 cases, the 
original stenting had been performed in a venous by-
pass graft. The rate of three-vessel disease ran as high 
as 28.0%. Angiographic data are shown in Table 2.
No routine intravascular ultrasound examination 
was done, while probable stent malapposition, as a 
commonly believed cause of ISR, was treated by high 
pressure non-compliant balloon inflation to the size 
of the proximal reference diameter in all cases.
Procedural results
The technical success rate of drug-eluting balloon in-
flation was 97.6%. In the remaining 2.4% (2 cases), 
drug-eluting balloon rupture occurred prematurely. 
In one of the 2 cases, further non-compliant balloon 
dilatation was needed because of residual in-stent re-
stenosis. In the other case a DES was implanted. In 
another 3 cases, the angiographic results were not 
acceptable after drug-eluting balloon inflation. In 2 
cases additional stent implantation was performed to 
treat dissection. In 1 further case, significant stenosis 
remained inside the treated stent, requiring high pres-
sure dilation with a conventional balloon. The over-
all procedural success rate was 93.9%. The most fre-
quently used drug-eluting balloon was Pantera Lux, in 
73.2%, followed by Dior in 18.3% and SeQuent Please 
in 8.5%. (See procedural data in Table 3.)
Clinical follow up
The median length of follow up was 28.0 (25.0-30.3) 
months. The MACE rate reached 19.5% at 12 months 
and 37.0% at 28 months. The rates of all-cause death 
were 6.1% and 12.3%, of myocardial infarction 2.5% 
and 9.0%, and of TLR 12.7% and 24.5%, at 12 and 
28 months, respectively. Two definite cases of stent 
thrombosis occurred: one was caused by a dissection 
within 24 hours after DEB intervention in a BMS re-
stenosis; the other was a very late stent thrombosis in 
a BMS implanted in a bifurcation lesion. One unex-
Table 2. Angiographic characteristics.
 Entire registry BMS-ISR (n=47) DES-ISR (n=35) p
BMS ISR, n (%) 47 (57.3) 47 (100.0) -  -
DES ISR, n (%) 35 (42.7) -  35 (100.0) -
Previous stent diameter (mm) 3.0 ± 0.4 3.0 ± 0.4 3.0 ± 0.4 0.542
Previous stent length (mm) 26.3 ± 15.6 23.1 ± 10.5 29.9 ± 19.4 0.069
Angiographic pattern of ISR
IB Stent margin, n (%) 6 (7.3) 3 (6.4) 3 (8.6) 0.706
IC Stent body, n (%) 25 (30.5) 12 (25.5) 13 (37.1) 0.259
ID Multifocal, n (%) 13 (15.9) 9 (19.1) 4 (11.4) 0.344
II Diffuse intra-stent, n (%) 29 (35.4) 16 (34.0) 13 (37.1) 0.772
III Diffuse-proliferative, n (%) 4 (4.9) 2 (4.3) 2 (5.7) 0.762
IV Total occlusion, n (%) 5 (6.1) 5 (10.6) 0 (0.0) 0.047
LM, n (%) 4 (4.9) 1 (2.1) 3 (8.6) 0.180
LAD, n (%) 28 (34.2) 14 (29.8) 14 (40.0) 0.335
CX, n (%) 16 (19.5) 10 (21.3) 6 (17.1) 0.640
IM, n (%) 1 (1.2) 1 (2.1) 0 (0.0) 0.385
RCA, n (%) 34 (41.5) 20 (42.6) 14 (40.0) 0.816
VBG, n (%) 3 (3.7) 2 (4.3) 1 (2.9) 0.739
True bifurcation lesion, n (%) 3 (3.9) 1 (2.1) 2 (6.5) 0.392
Small vessel (≤2.5 mm), n (%) 14 (17.1) 11 (23.4) 3 (8.6) 0.078
Treated vessel/patient, n/n 82/82 47/47 35/35 1.000
Three-vessel disease, n (%) 23 (28.0) 10 (21.3) 13 (37.1) 0.114
BMS – bare metal stent; DES – drug-eluting stent; ISR – in-stent restenosis; LM – left main coronary artery; LAD – left anterior descending coronary artery; 
CX – circumflex coronary artery; IM – ramus intermedius; RCA – right coronary artery; VBG – vein bypass graft.
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plained sudden death two days after the procedure 
was observed in the DES-ISR group and was subse-
quently classified as probable stent thrombosis. The 
angiographic follow-up rate was 51.2%. Clinical fol-
low-up data are shown in Table 4. There were no sig-
nificant differences between the types of drug-elut-
ing balloons as regards the clinical endpoints: TLR 
(p=0.467), MACE (p=0.633). See Table 5 for details.
Predictors of MACE and TLR
During the 28-month follow up we found two inde-
pendent predictors of MACE and TLR by multivari-
ate Cox analysis. Diffuse or occlusive type of resteno-
sis was a significant predictor of TLR, with a hazard 
ratio of 2.070 (95% CI 1.047-4.093; p=0.036) and a 
significant predictor of MACE, with a hazard ratio of 
2.056 (95% CI 1.101-3.838; p=0.024). Renal insuffi-
ciency independently predicted a higher rate of TLR, 
hazard ratio 9.618 (95% CI 1.710-54.094; p=0.010), 
and a higher rate of MACE, hazard ratio 7.810 (95% 
CI 2.691-22.667; p<0.001). Diabetes and the type of 
the treated DES had no independent effect on TLR 
or MACE in this setting.
BMS versus DES restenosis
It is well-known that DES restenosis is different from 
BMS restenosis regarding the underlying mecha-
nism, angiographic pattern and appearance. More-
Table 3. Procedural data.
 Entire registry BMS-ISR (n=47) DES-ISR (n=35) p
Radial approach, n (%) 68 (82.9) 41 (87.2) 27 (77.1) 0.223
Predilation (conventional), n (%) 82 (100.0) 47 (100.0) 35 (100.0) 1.000
Predilation (cutting), n (%) 1 (1.2) 0 (0.0) 1 (2.9) 0.244
Thrombus aspiration, n (%) 2 (2.4) 2 (4.3) 0 (0.0) 0.217
IVUS use, n (%) 3 (3.7) 1 (2.1) 2 (5.7) 0.392
Number of DEB treated lesions, n 82 47 35
DEB/patient ratio, n/n 82/82 47/47 35/35 1.000
Type of DEB    0.316
- Dior, n (%) 15 (18.3) 9 (19.1) 6 (17.1) 
- SeQuent Please, n (%) 7 (8.5) 1 (2.1) 6 (17.1) 
- Pantera Lux, n (%) 60 (73.2) 37 (78.7) 23 (65.7) 
DEB diameter (mm) 3.08 ± 0.42 3.02 ± 0.43 3.16 ± 0.38 0.110
DEB length (mm) 22.8 ± 5.2 22.7 ± 5.1 23.0 ± 5.4 0.799
Inflation time (s) 49.0 ± 6.7 48.2 ± 6.2 50.1 ± 7.2 0.204
Kissing dilation, n (%) 3 (3.7) 1 (2.1) 2 (5.7) 0.392
Successful DEB inflation, n (%) 80 (97.6) 46 (97.9) 34 (97.1) 0.832
Postdilation after DEB, n (%) 2 (2.4) 0 (0.0) 2 (5.7) 0.097
Bailout stent implantation, n (%) 3 (3.7) 3 (6.4) 0 (0.0) 0.128
- Coronary dissection, n (%) 2 (2.4) 2 (4.3) 0 (0.0) 0.217
- Acute recoil (stenosis≥50%), n (%) (%) 1 (1.2) 1 (2.1) 0 (0.0) 0.385
Angiographic success, n (%) 77  (93.9) 44 (93.6) 33 (94.3) 0.900
IVUS – intravascular ultrasound; DEB – drug-eluting balloon.
Table 4. Follow-up data of entire registry at 28 months; BMS-ISR and DES-ISR subgroups at 12 and 28 months.
 Overall BMS-ISR DES-ISR BMS-ISR (n=47) DES-ISR (n=35) p 
  12 month 12 month 28 month 28 month 
Overall death, n (%) 10 (12.3) 4 (8.5) 1 (2.9) 6 (12.9) 4 (11.4) 0.828
ST, n (%) 3 (3.8) 1 (2.1) 1 (2.9) 2 (4.5) 1 (2.9) 0.724
AMI, n (%) 6 (9.0) 2 (4.4) 0 (0.0) 4 (9.5) 2 (8.8) 0.620
TLR, n (%) 18 (24.5) 6 (13.3) 4 (11.8) 9 (21.1) 9 (29.0) 0.687
MACE, n (%) 29 (37.0) 11 (23.4) 5 (14.3) 16 (34.7) 13 (40.8) 0.994
Angiographic follow-up rate, n (%) 42 (51.2) 14 (29.8) 14 (40.0) 24 (51.1) 18 (51.4) 0.211
ST – (definite and probable) stent thrombosis according to Academic Research Consortium; AMI – acute myocardial infarction; TLR – ischemia driven 
target lesion revascularization; MACE – major adverse cardiac events.
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over, DES restenosis reacts differently to treatment 
than does BMS restenosis. Baseline demographic and 
angiographic data were somewhat different in the 
following ways: the rate of previous bypass surgery 
was significantly higher (25.7% vs. 6.4%, p=0.014) 
and the previous implanted stent length was slight-
ly higher (29.9 ± 19.4 vs. 23.1 ± 10.5 mm, p=0.069) 
in our patient population, while no patient in the 
DES-ISR group had occlusive restenosis (0.0% vs. 
10.6%, p=0.047). There were no differences between 
the DES-ISR and BMS-ISR groups regarding the 
clinical endpoints. (See details in Table 4.) The Ka-
plan–Meier TLR-free and MACE-free survival rates 
were slightly lower after the first year in the DES-ISR 
group; these curves are shown in Figures 1 and 2.
Discussion
Our single-center prospective registry represents a 
kind of evidence of the efficacy of drug-eluting bal-
loon treatment in patients with BMS and DES reste-
nosis. The Pantera Lux, SeQuent Please, and Dior 
balloons we used proved to be effective during the 
first year, as the rate of TLR was below 14% in both 
BMS-ISR and DES-ISR groups. The increase in the 
next 16 months was 7.8% versus 17.2% in the BMS-
ISR versus DES-ISR group, respectively. However, 
the results were less favorable after 28 months of fol-
low up, given the continuous increase in TLR, partic-
ularly in the DES-ISR group. Our findings confirmed 
the so-called late catch-up phenomenon among pa-
Table 5. Follow-up data at 28 months according to type of drug-eluting balloon.
 Entire registry Dior SeQuent Please Pantera Lux 
  (n=15) (n=7) (n=60) p
Overall death, n (%) 10 (12.3) 2 (13.3) 1 (14.3) 7 (11.8) 0.971
ST, n (%) 3 (3.8) 1 (6.7) 0 (0.0) 2 (3.5) 0.687
AMI, n (%) 6 (9.0) 1 (6.7) 0 (0.0) 5 (11.0) 0.715
TLR, n (%) 18 (24.5) 2 (14.4) 2 (28.6) 14 (26.1) 0.710
MACE, n (%) 29 (37.0) 4 (26.7) 2 (28.6) 23 (40.9) 0.716
Angiographic follow-up rate, n (%) 42 (51.2) 6 (40.0) 5 (71.4) 31 (51.7) 0.008
ST – (definite and probable) stent thrombosis according to ARC; AMI – acute myocardial infarction; TLR – ischemia driven target lesion revascularization; 



























































Figure 1. Kaplan–Meier survival curve for target lesion revascu-
larization (TLR) in the BMS-ISR and DES-ISR groups. TLR rate 
was 21.1% versus 29.0% at 28-month follow up in the BMS-ISR 
versus DES-ISR group, respectively (log-rank p=0.687).
Figure 2. Kaplan–Meier survival curve for major adverse cardiac 
events (MACE) in the BMS-ISR and DES-ISR groups. The to-
tal MACE rate was 34.7% versus 40.8% at 28-month follow up 
in the BMS-ISR versus DES-ISR group, respectively (log-rank 
p=0.994).
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tients treated with drug-eluting balloons because of 
DES restenosis, as we found the TLR rate to be more 
than double after one year of follow up. Sgueglia et 
al, in a meta-analysis of TLR after drug-eluting bal-
loon treatment of DES restenosis, observed almost a 
doubling of the rate between 6 and 12 months’ follow 
up, whereas the TLR rate remained stable over the 
same period after BMS restenosis treatment.30
The investigated patients had a high risk of reste-
nosis, with high rates of diabetes mellitus and three-
vessel disease, and an ISR pattern of diffuse, diffuse-
proliferative and total occlusion. A slightly higher 
TLR and MACE rate, though not significantly so, was 
found in the DES ISR group compared to the BMS 
ISR group after drug-eluting balloon inflation during 
long-term clinical follow up, although the sample siz-
es of the subgroups were relatively small.
Our first-year results are comparable with those of 
recently published registries. The Spanish DIOR mul-
ticenter registry showed an 11.9% TLR rate at 1-year 
follow up of patients who underwent drug-eluting bal-
loon treatment after DES and BMS ISR.19 The TLR 
rate was slightly higher in the case of DES ISR (14.8% 
vs. 9.2%; p: NS). The SeQuent Please World Wide 
Registry, which is currently the largest drug-eluting 
balloon registry, yielded a higher TLR rate after DES 
ISR treatment compared to BMS ISR treatment (9.6% 
vs. 3.8%; p<0.001), after 9.4 months of follow up. The 
difference between outcomes may be a consequence 
of local antiproliferative drug resistance in the DES 
population, while in case of BMS ISR lesions the local 
drug therapy may have had a positive response.
Mechanisms of BMS and DES ISR
BMS eliminated the main grounds for restenosis af-
ter balloon angioplasty, but neointimal hyperplasia re-
mained the main cause of BMS ISR. DES, with their 
antiproliferative drug release, inhibit this undesirable 
process, although this drug also defers the endotheliza-
tion of the stent surface, thus prolonging the risk of stent 
thrombosis. DES ISR is no longer a rare entity, due to 
the fact that DESs are implanted into far more complex 
lesions and to adverse phenomena such as stent under-
expansion/malapposition, drug failure, or strut fracture.7
Management of BMS and DES ISR
The invasive management of a coronary artery with 
ISR, even in the previous standard treatment with 
BMS, remains challenging. Some randomized stud-
ies comparing DES with balloon angioplasty,8,9 or 
even with brachytherapy,12-14,31 and real life experi-
ence with DES in the treatment of BMS ISR11 from 
the near past, all proved the beneficial use of DES in 
patients with BMS ISR. The rate of TLR after DES 
therapy ranges between 10.1% and 19.0% during 
long-term follow up. In these trials, the effectiveness 
of balloon angioplasty and brachytherapy regarding 
TLR was outperformed by DES. However, the rela-
tively high numbers of repeat ISR in DES after ISR 
treatment may raise some questions about the use-
fulness of the method.15 Drug-eluting balloons have 
a favorable effect on BMS ISR treatment without a 
new stent layer inside the ISR. The PACCOCATH 
ISR II randomized multicenter trial revealed a re-
duced repeated TLR rate after drug-eluting balloon 
treatment of ISR at 2 years (6.0% vs. 37.0%) and at 
5 years (9.3% vs. 38.9%), where conventional balloon 
angioplasty was the comparator.16,17 In the PEPCAD 
II study, the SeQuent Please drug-eluting balloon 
was compared to the Taxus paclitaxel-eluting stent as 
treatment options after BMS ISR. The study revealed 
that there was no statistically significant difference in 
1-year MACE between the two modalities; however, 
the in-segment late loss (0.17 ± 0.42 mm vs. 0.38 ± 
0.61 mm) and binary restenosis rate (7% vs. 20%) of 
the drug-eluting balloon group were superior to those 
of the Taxus DES.18
On the other hand, there are observations sug-
gesting that the treatment methods that were suc-
cessfully utilized in BMS ISR received a different 
response in DES ISR. The study of Steinberg et al 
demonstrated that DES implantation is less favor-
able in DES ISR compared to BMS ISR, with target 
vessel revascularization rates at 1 year of 22.2% vs. 
10.3%, respectively.10 To treat DES ISR, the ISAR-
DESIRE 3 trial confirmed that the drug-eluting bal-
loon is not inferior to a paclitaxel-eluting stent in 
terms of restenosis, while both were superior to bal-
loon angioplasty: the rates of TLR were 22.1% vs. 
13.5% vs. 43.5%, respectively.22 Other studies, such 
as PEPCAD-DES (TLR 15.3% vs. 36.8%) and the 
investigation by Habara et al (TLR 4.3% vs. 41.7%), 
also confirmed the superiority of drug-eluting balloon 
over plain balloon angioplasty during 6-month fol-
low up.20,21 Even so there is only a small amount of 
evidence proving the advantages of drug-eluting bal-
loon treatment in ISR regarding the clinical outcome. 
Some issues are still not clearly understood, such as 
the patient selection for drug-eluting balloon therapy 
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and the factors that may influence the long-term suc-
cess rate in the future. 
Summary
The use of drug-eluting balloons is considered to 
be one of the potentially beneficial methods in set-
tings of ISR in either BMS or DES. Our results 
demonstrate a good mid-term and moderate long-
term clinical success rate in patients with high car-
diovascular risk, with cumulative ischemia-driven 
TLR rates of 12.7% and 24.5% and MACE rates of 
19.5% and 37.0% at 12 and 28 months, respectively. 
In this registry we found slightly less favorable re-
sults in patients with DES ISR compared to BMS 
ISR beyond one year. However, randomized clinical 
trials and larger patient population registries with 
longer follow-up durations will be required to prove 
the effectiveness of drug-eluting balloons in ISR le-
sions.
Promising “stentless” percutaneous coronary 
intervention techniques
Recently, two new options have been devised to tack-
le the problem of ISR. Besides the drug-eluting bal-
loon, which is a stentless delivery system of a locally 
acting cytostatic drug, the other promising opportuni-
ty is the drug-eluting bioabsorbent vascular scaffold-
ing, which offers all the necessary advantages to effec-
tively reduce or eliminate ISR. Although the prelimi-
nary clinical observations are promising,32 we should 
still wait for the longer-term results from a larger 
number of patients.
Limitations
This study was a non-randomized single-center 
registry. The primary endpoint was clinically driv-
en TLR; hence, no routine control angiography 
was performed. Lesions were estimated visual-
ly. This registry was underpowered to detect dif-
ferences in clinical outcomes between the three 
types (Dior, SeQuent Please and Pantera Lux) of 
drug-eluting balloons. During the procedures, rou-
tine intravascular ultrasound imaging was not per-
formed.
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